Stinkens Kirsten, Mathieu Chantal
Department of Endocrinology UZ Leuven, UZ Gasthuisberg, Leuven, Belgium.
Eur Endocrinol. 2016 Mar;12(1):33-34. doi: 10.17925/EE.2016.12.01.33. Epub 2016 Mar 15.
The use of sodium-glucose cotransporter 2 inhibitors is associated with an increased risk of diabetic ketoacidosis. This risk has been reported in particular in off-label use of these agents in type 1 diabetes, but reports of risks in type 2 diabetes patients also exist. In type 2 diabetes ketoacidosis is rare and is present particularly in patients who have undergone prolonged starvation, serious infection, alcohol abuse or surgery. The pleiotropic advantages of sodium-glucose cotransporter 2 inhibitors do not outweigh the risk for a diabetic ketoacidosis, but caution is warranted.
使用钠-葡萄糖协同转运蛋白2抑制剂会增加糖尿病酮症酸中毒的风险。这种风险尤其在1型糖尿病患者中这些药物的非标签使用中被报道过，但2型糖尿病患者的风险报告也存在。在2型糖尿病中，酮症酸中毒很少见，尤其在经历长期饥饿、严重感染、酗酒或手术的患者中出现。钠-葡萄糖协同转运蛋白2抑制剂的多效性优势并不超过糖尿病酮症酸中毒的风险，但仍需谨慎。
